Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

This study tests a combination of two immunotherapy drugs — brentuximab vedotin and nivolumab — for patients with classical Hodgkin lymphoma that has returned or stopped responding after initial treatment, and who are not candidates for a stem cell transplant. **You may be eligible if...** - You have been diagnosed with classical Hodgkin lymphoma confirmed by biopsy - Your disease has relapsed or not responded after one prior line of therapy - You are not eligible for a stem cell transplant (due to age, other health conditions, or personal preference) - You are in reasonably good health (ECOG 0-2) - You can provide a tissue sample from your cancer **You may NOT be eligible if...** - You have nodular lymphocyte-predominant Hodgkin lymphoma (a different subtype) - You have had more than one prior line of treatment - You have significant organ damage or other serious health problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.